|
Jul 28
|
The 17% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 151%
|
|
Jun 18
|
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
|
|
May 22
|
Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares
|
|
May 8
|
Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...
|
|
May 7
|
Stoke Therapeutics First Quarter 2024 Earnings: Beats Expectations
|
|
May 6
|
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 6
|
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
|
|
Apr 29
|
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
|
|
Apr 29
|
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
|
|
Apr 25
|
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
|
|
Apr 17
|
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
|
|
Apr 4
|
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 28
|
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
|
|
Mar 27
|
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
|
|
Mar 26
|
Stoke Therapeutics Announces Proposed Public Offering
|
|
Mar 26
|
Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients
|
|
Mar 26
|
Stoke shares surge on updated results for Dravet drug
|
|
Mar 25
|
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 25
|
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
|
|
Mar 25
|
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
|